These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 23702337)

  • 1. Trends and inequities in colorectal cancer screening participation in Ontario, Canada, 2005-2011.
    Honein-AbouHaidar GN; Baxter NN; Moineddin R; Urbach DR; Rabeneck L; Bierman AS
    Cancer Epidemiol; 2013 Dec; 37(6):946-56. PubMed ID: 23702337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population-based estimate of the extent of colorectal cancer screening in Ontario.
    Rabeneck L; Paszat LF
    Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ontario's ColonCancerCheck: results from canada's first province-wide colorectal cancer screening program.
    Rabeneck L; Tinmouth JM; Paszat LF; Baxter NN; Marrett LD; Ruco A; Lewis N; Gao J
    Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):508-15. PubMed ID: 24443406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of lower gastrointestinal endoscopy and fecal occult blood test in the 2007 Swiss Health Interview Survey respondents aged 50 years and older.
    Spaeth A; Zwahlen M
    Endoscopy; 2013 Jul; 45(7):560-6. PubMed ID: 23780844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a population-based colorectal cancer screening program on local health services demand in Italy: a 7-year survey in a northern province.
    Parente F; Marino B; Ardizzoia A; Ucci G; Ilardo A; Limonta F; Villani P; Moretti R; Zucchi A; Cremaschini M; Pirola ME
    Am J Gastroenterol; 2011 Nov; 106(11):1986-93. PubMed ID: 21670773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008.
    Choi KS; Lee HY; Jun JK; Shin A; Park EC
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1070-7. PubMed ID: 22004224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Colorectal Cancer Screening: Does Rurality Play a Role?
    Ojinnaka CO; Choi Y; Kum HC; Bolin JN
    J Rural Health; 2015; 31(3):254-68. PubMed ID: 25599819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer test use--Maryland, 2002-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer screening in Canada: results of a national survey.
    Sewitch MJ; Fournier C; Ciampi A; Dyachenko A
    Chronic Dis Can; 2008; 29(1):9-21. PubMed ID: 19036219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer screening behavior in women attending screening mammography: longitudinal trends and predictors.
    Carlos RC; Fendrick AM; Abrahamse PH; Dong Q; Patterson SK; Bernstein SJ
    Womens Health Issues; 2005; 15(6):249-57. PubMed ID: 16325138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vital signs: colorectal cancer screening among adults aged 50-75 years - United States, 2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Jul; 59(26):808-12. PubMed ID: 20613704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
    Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the impact of public health initiatives on trends in fecal occult blood test participation in Ontario.
    Honein-AbouHaidar GN; Rabeneck L; Paszat LF; Sutradhar R; Tinmouth J; Baxter NN
    BMC Cancer; 2014 Jul; 14():537. PubMed ID: 25062552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in colorectal cancer screening with home-based fecal occult blood tests in adults ages 50 to 64 years, 2000-2008.
    Bandi P; Cokkinides V; Smith RA; Jemal A
    Cancer; 2012 Oct; 118(20):5092-9. PubMed ID: 22434529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early detection of bowel cancer in occupational surveillance examinations: switching from a guaiak-based to an immunochemical fecal occult blood test].
    Webendörfer S; Riemann JF
    Dtsch Med Wochenschr; 2014 Jan; 139(3):79-83. PubMed ID: 24089288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Rates of Colon Cancer Screening Use in Winnipeg, Canada: The Experience of a Universal Health-Care System with an Organized Colon Screening Program.
    Decker KM; Demers AA; Nugent Z; Biswanger N; Singh H
    Am J Gastroenterol; 2015 Dec; 110(12):1640-6. PubMed ID: 26169513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of fecal occult blood test (FOBT) completion among low-income adults.
    Greiner KA; James AS; Born W; Hall S; Engelman KK; Okuyemi KS; Ahluwalia JS
    Prev Med; 2005 Aug; 41(2):676-84. PubMed ID: 15917068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal occult blood test screening uptake among immigrants from Muslim majority countries: A retrospective cohort study in Ontario, Canada.
    Vahabi M; Lofters A; Wong JP; Ellison L; Graves E; Damba C; Glazier RH
    Cancer Med; 2019 Nov; 8(16):7108-7122. PubMed ID: 31568705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.